Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Rbv-Dasabuvir'

Rbv-Dasabuvir published presentations and documents on DocSlides.

Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir
Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir
by vamput
Prepared by: . Sophie . Woolston. , MD and David H...
3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in
3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in
by conchita-marotz
SAPPHIRE-I. Phase 3. . Treatment. . Naïve. Fel...
3 D (Paritaprevir
3 D (Paritaprevir
by myesha-ticknor
-Ritonavir. -Ombitasvir . + Dasabuvir) . + RBV in...
3D (Paritaprevir-Ritonavir-
3D (Paritaprevir-Ritonavir-
by ava
Ombitasvir + . Dasabuvir) +/- . RBV in . GT1b. PEA...
Ombitasvir-Paritaprevir
Ombitasvir-Paritaprevir
by tatiana-dople
-. Ritonavir . and Dasabuvir . + RBV in . GT1. SA...
Ombitasvir-Paritaprevir-Ritonavir
Ombitasvir-Paritaprevir-Ritonavir
by sherrill-nordquist
. and Dasabuvir +/- . RBV in . GT1b. PEARL-II. P...
OBV/PTV/r DSV Open label
OBV/PTV/r DSV Open label
by kittie-lecroy
≥ 18 years. Chronic HCV infection. Genotype 1. ...
OBV/PTV/r DSV RBV OBV/PTV/r
OBV/PTV/r DSV RBV OBV/PTV/r
by ellena-manuel
DSV . placebo. Randomisation*. Partial blind. 1...
SAPPHIRE-I
SAPPHIRE-I
by ellena-manuel
Feld JJ. NEJM . 2014;370:1594-1603. SAPPHIRE-I . ...
Ombitasvir-
Ombitasvir-
by kittie-lecroy
Paritaprevir. -. Ritonavir. . and . Dasabuvir. ...
Design
Design
by test
PTV150/r + OBV + . DSV . + RBV. PTV150/r + . DSV...
3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in
3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in
by yoshiko-marsland
TURQUOISE-II. Phase 3. . Treatment. Naïve and ...
Out With the Old and In With the New, Again?
Out With the Old and In With the New, Again?
by test
Out With the Old, In With the New. Current Standa...
TURQUOISE-I
TURQUOISE-I
by natalia-silvester
OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...
C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3
C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3
by UnicornLove
C-WORTHY/D. GZR + EBR + RBV. GZR + EBR + RBV. N =...
Daclatasvir + Sofosbuvir + RBV in GT3
Daclatasvir + Sofosbuvir + RBV in GT3
by sophia2
. with Advanced Liver Disease. ALLY-3+ Study. Phas...
PEG alfa-2a RBV versus
PEG alfa-2a RBV versus
by alexa-scheidler
. PEG alfa-. 2a . versus. INF RBV . APRICOT S...
SOF + RBV
SOF + RBV
by debby-jeon
SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label....
SOF + EBR + GZR + RBV
SOF + EBR + GZR + RBV
by test
N = 12. N = 13. W24. W16. SOF + EBR + GZR + RBV. ...
MK3 MK3 + RBV
MK3 MK3 + RBV
by min-jolicoeur
Randomisation. Open-label. W8. * Liver biopsy or ...
Ombitasvir-Paritaprevir-Ritonavir
Ombitasvir-Paritaprevir-Ritonavir
by mitsue-stanley
. and Dasabuvir + RBV in GT1. SAPPHIRE-I. Phase ...
TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-I
TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-I
by eloise
20. th. International AIDS Conference. • . Melb...
TURQUOISE-II
TURQUOISE-II
by pasty-toler
OBV/PTV/r . + . DSV . + RBV. OBV/PTV/r + . DSV . ...
TURQUOISE-II
TURQUOISE-II
by giovanna-bartolotta
OBV/PTV/r . + . DSV . + RBV. OBV/PTV/r + . DSV . ...
FISSION Design Objective
FISSION Design Objective
by travis
Non . inferiority. of SOF + RBV : SVR. 12. (. 2-...
Pharmacometrics and Biostatistics Interactions at the FDA
Pharmacometrics and Biostatistics Interactions at the FDA
by byrne
Jeffry Florian, Ph.D.. Division of Pharmacometrics...
Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology
Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology
by badra
Duke University School of Medicine. Durham, North ...
How to optimize treatment of G1 patients?
How to optimize treatment of G1 patients?
by KissesForYou
Prof. G. K. K. Lau 2012. Standard of care (SOC) ...
NS5A and polymerase inhibitors
NS5A and polymerase inhibitors
by LoveBug
Mark Sulkowski, MD. Professor of Medicine. Johns H...
Are (exogenous) interferons
Are (exogenous) interferons
by amey
really necessary?. Peter . Ferenci. Medical Univer...
522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc
522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc
by daisy
B7AB8DW10--62712/0216U28411204- f-25189455DVReWbVT...
M.W. Fried , 1 M. Buti,
M.W. Fried , 1 M. Buti,
by iamamercy
2. G.J. Dore,. 3. P. Ferenci,. 4. . I. Jacobson...
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
by webraph
Sameh W. Boktor, MD, MPH. Medical Epidemiologist. ...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by trish-goza
IAPAC African Regional Capacity-Building Hub. Bas...
Hepatitis C Imtiaz Alam, M.D.
Hepatitis C Imtiaz Alam, M.D.
by olivia-moreira
Medical Director, Austin Hepatitis Center. 1. Hep...
Updates in Treatment of Hepatitis C
Updates in Treatment of Hepatitis C
by myesha-ticknor
Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by danika-pritchard
IAPAC African Regional Capacity-Building Hub. Bas...
Updates in Treatment of Hepatitis C
Updates in Treatment of Hepatitis C
by cheryl-pisano
Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...
Prevention strategies for HIV/HCV co infection
Prevention strategies for HIV/HCV co infection
by giovanna-bartolotta
Isabelle Andrieux-Meyer, MD. Médecins Sans Front...
Updated Guidelines for Managing HIV/HCV Co-Infection
Updated Guidelines for Managing HIV/HCV Co-Infection
by karlyn-bohler
John J . Faragon. , . PharmD. , BCPS, AAHIV-P. Re...